Pressemeddelelse

Alligator Bioscience Announces Poster Presentation on Neo-X-Prime Bispecific Antibody ATOR-4066 at SITC Annual Meeting 2023

Presentation highlights ATOR-4066's superior anti-tumor effect and confirms CEACAM5-conditional activation of CD40 expressing cells
Data show immunological memory displayed in vivo and homologous tumors cleared upon rechallenge
Enhanced effect of ATOR-4066 when combined with anti-PD-1
Data strongly emphasize the potential of ATOR-4066 as monotherapy and as a checkpoint inhibitor combination partner

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces a poster presentation on ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, at the 2023 SITC (Society for Immunotherapy of Cancer) Annual Meeting, being held in San Diego November 1-5, 2023.

The presentation, entitled "Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro", outlines the use of CEACAM5 expressing tumor models to study the anti-tumor efficacy of ATOR-4066 and to analyze induction of immunological memory in vivo.

The presentation highlights that:

ATOR-4066 has a superior anti-tumor effect compared to a CD40 monospecific antibody
ATOR-4066 activation of CD40 expressing cells is CEACAM5-conditional with no activation in absence of CEACAM5 indicating a potential for a wide therapeutic window
ATOR-4066 is well positioned, with distinct advantages compared to other CD40 or CEACAM5 targeting therapies, such as strong anti-tumor effect in vivo also in larger tumors with heterogenous CEACAM5 expression
ATOR-4066 induces immunological memory in vivo and were able to clear homologous tumors upon re-challenge
Combining ATOR-4066 with anti-PD-1 in vitro in a mixed lymphocyte reaction assay[1] produces a clear synergistic effect observed on reactivation of exhausted T cells as measured by an increase in interferon gamma production
Using dissociated tumor cells from gastric cancer patients, ATOR-4066 induced activation of multiple tumor infiltrating immune cell populations (i.e. B cells, macrophages and T cells)

"To have this abstract accepted for presentation at this year's prestigious SITC annual meeting is a testament both to the promise of ATOR-4066 and to the diligent work of the Alligator scientific team," said Søren Bregenholt, CEO of Alligator Bioscience. "These data emphasize the potential of ATOR-4066 both as a monotherapy and as a combination partner for checkpoint inhibitors to further enhance the immune response in tumors and we continue to advance ATOR-4066 towards the clinic."

Poster Presentation Details
Abstract Number: 837
Title: Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro
Date/Time: Friday 3 November, 2023, 9.00 am - 7.00 pm PDT
Presenter: Ida Uddbäck, Scientist, Alligator Bioscience
Location: Exhibit Halls A and B1, San Diego Convention Center

[1] Mixed lymphocyte reaction (MLR) – a common method for assessing the cellular immune response.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.